Maggio - Giugno - Sigot.org

Geriatria
BIBLIOGRAFIA
1 HYLEK E.M., GO A.S., CHANG Y. et al.: Effect of
intensity of oral anticoagulation on stroke severity
and and mortality in atrial fibrillatio. NEJM 2003;
349; 1019-1026.
2. SMITH N.L., PSATY B.M., FURBERG C.D. et al.:
Temporal trends in the use of anticoagulants a-
mong older adults with atrial fibrillation. Arch. Int.
Med. 1999; 159: 1574-1578.
3. GARCIA D., REGAN S., CROWTHER M. et al.:
Warfarin maintenance dosing patterns in clinical
practice. Implication for safer anticoagulation in
the elferly population. Chest 2005; 127: 2049-
2056.
4. WOODHOUSE K.W., JAMES O.F.: Hepatic drug
metabolism and ageing. Br. Med. Bull. 1990; 46: 22-35.
5. SOTANIEMI E.A., ARRANTOA J., PELKONEN
O. et al.: Age and cytocrome 450-linked drug metabolism
in humans: an analysis of 226 subjects with
equal histopatologic conditions. Clin. Pharmacol.
Ther. 1997; 61: 331-339.
6. LOGUERCIO C., TARANTO D., VITALE L.M. et
al.: Effect of liver cirrhosis and age on the glutathione
concentration in the plasma, erythrocytes,
and gastric mucosa of man. Free Radic. Biol. Med.
1996; 20: 483-488.
7. GEDGE J., ORME S., HAMPTON K.K. et al.: A
comparison of a low dose warfarin induction regimes
with the modified Fenerty regimen in elderly
impatients. Age Ageing 2000; 29: 31-34.
8. ROBERTS G.W., DRUSKEIT T., JORGENSEN
L.E. et al.: Comparison of an age adjusted warfarin
loading protocol with empirical dosing and
Fenerty’s protocol. Aust. J. NZ J. Med. 1999; 29:
731-736.
9. ACCP conference on antithrombotic and
Thrombolytic therapy. Chest 2004; 126: 204S-233S.
10. Risk factors for stroke and efficacy of antithrombotic
therapy in atrial fibrillation. Analysis of
pooled data of five randomized controlled trials.
Arch. Int. Med. 1994; 154: 1449-1457.
11. FITZMAURICE D.A., MURRAY A.T., MCCHA-
HON D. et al.: Self management of oral anticoagulation:
randomized trial. BMJ 2005; 331: 1057-1063.
12. PETERSEN P., BOYSEN G., GODFREDSEN J. et
al.: Placebo-controlled randomized trial of warfarin
and aspirin for prevention of thromboembolic complication
in chronic atrial fibrillation. The Copenhagen
AFASAK study. Lancet 1989; 1: 175-179.
12. OLSSON S.B.: Executive Steering committee on
behalf of the SPORTIF III investigators. Stroke prevention
with the oral direct thrombi inibitor ximelgratan
compared with warfrinin patients with nonvalvular
atrial fibrillation (SPORTIF III): randomized
controlled trial. Lancet 2003; 362: 1691-1698.
Vol. XVIII n. 3 - Maggio/Giugno 2006 167